Recent research paper titled "Impact of Persistent Pulmonary Hypertension of the Newborn in Neonates with ...
FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...
Exercise PH — measured by the mPAP/CO slope — may predict survival in patients with normal or mildly elevated pulmonary arterial pressure.
A possibly more precise risk model showed Adempas helped PAH patients at intermediate risk of death arrive at more favorable ...
A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...
A new molecular imaging technique-18F-FAPI PET-can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker ...
F-FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...
Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...
8h
Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.54 and traded as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback